Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

0.4400 +0.0004 (+0.09%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,159
Open 0.4459
Bid (Size) 0.4400 (20)
Ask (Size) 0.4750 (2)
Prev. Close 0.4396
Today's Range 0.4400 - 0.4459
52wk Range 0.4311 - 1.350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy
Via Investor Brand Network
Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer
Via Investor Brand Network

Performance

YTD
-27.83%
-27.83%
1 Month
-14.65%
-14.65%
3 Month
-6.48%
-6.48%
6 Month
-35.29%
-35.29%
1 Year
-66.16%
-66.16%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma
Via Investor Brand Network
Gene Signature Could Predict NSC Lung Cancer Response to Immunotherapy
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
Via Investor Brand Network
Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Via Investor Brand Network
The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Scientists Uncover Vital T-Cells in Kids’ Brains That Could Fight Brain Cancers
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter
Via Investor Brand Network
Shining Spotlight on How Vitiligo Could Be Connected to Other Autoimmune Disorders
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Agreement for Million-Dollar Exercise of Outstanding Warrants
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces January Analyst, Investor Webinar
Via Investor Brand Network
New Research Redefines Pathophysiology of Rheumatoid Arthritis, Paves Way for Precision Treatments
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs
Via Investor Brand Network
Exposures COVID-19
Many Fellowship Programs for Infectious Disease Specialists Remain Unfilled in US
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.